Article Text

Download PDFPDF
Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis
  1. Laura Obici1,
  2. Antonella Meini2,
  3. Marco Cattalini2,
  4. Silvana Chicca3,
  5. Marco Galliani3,
  6. Simona Donadei1,
  7. Alessandro Plebani2,
  8. Giampaolo Merlini1
  1. 1Amyloidosis Research and Treatment Center, Biotechnology Research Laboratories and Department of Biochemistry, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
  2. 2Immuno-Rheumatology Unit, Clinica Pediatrica, University of Brescia, Brescia, Italy
  3. 3Nephrology Unit, Ospedale Sandro Pertini, Roma, Italy
  1. Correspondence to Professor Giampaolo Merlini, Amyloid Research and Treatment Center, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo Viale Golgi, 19, 27100 Pavia, Italy; gmerlini{at}

Statistics from

Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) is a dominantly inherited autoinflammatory disease characterised by recurrent episodes of fever, arthritis and serositis. In adulthood, inflammation often becomes persistent1 and AA amyloidosis may occur. Evidence of dysregulated secretion of proinflammatory cytokines, particularly interleukin 1 (IL-1) beta, in autoinflammatory diseases recently supported anakinra, the recombinant IL-1 receptor antagonist, as a target therapy for most of these conditions.2 3 In TRAPS, response to anakinra was reported in two case reports and in one prospective trial, in which five patients were treated for a mean duration of 11.4 months.4,,6 However, longer follow-up and additional observations are warranted. We report the long-term efficacy and safety of anakinra in seven TRAPS patients with and without …

View Full Text


  • Patient consent Obtained.

  • Funding This work was supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 200923, Eurotraps project.

  • Competing interest None.

  • Ethical approval The Institutional review Board of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, approved the storage and use of biological samples and the use of patients' clinical data for research purposes.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.